Rob J

Recent Posts

Medtech: how to succeed in Europe

20th March 2014
Amidst a currently effervescent biotech scene, medtech is suffering. Sector newsflow is dominated by layoffs, regulatory escalation and a harsh fiscal environment. In this context, it is appealing...
Learn More

It is critical for US biotech companies to understand the needs of European payers

17th October 2013
There is increasing divergence between the evidence regulators need for approval, and that needed by payers for reimbursement. Whilst ignoring the needs of European payers before entering Phase 3...
Learn More

A genome's got to know it's limitations

28th January 2013
The UK Government has become the latest believer in the genome. In December 2012, the prime minister of the United Kingdom announced an ambitious plan to fully sequence the genomes of 100,000 Britons...
Learn More

Biotech in Israel: A Land of Promise

18th May 2012
Israeli medtech is widely regarded as world-class both by investors and the industry at large. Israeli biotech, on the other hand, does not (yet) enjoy similar standing. True, there are some notable...
Learn More

FDA Approvals Provide Reason For Cheer

14th March 2012
Both biotech and pharma investors are in despair. KPMG recently concluded that returns on R&D investment among the 30 leading drug companies fell by 50% since 1990. At a 10% rate of return last year,...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-26 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.